Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine
Triple-positive breast cancer (TPBC), defined by the co-expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), poses unique therapeutic challenges due to complex signaling interactions and resulting treatment resistance. This review sum...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1467033/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556768140820480 |
|---|---|
| author | Xiu Yang Daxin Yang Xue Qi Xiujuan Luo Guangmei Zhang |
| author_facet | Xiu Yang Daxin Yang Xue Qi Xiujuan Luo Guangmei Zhang |
| author_sort | Xiu Yang |
| collection | DOAJ |
| description | Triple-positive breast cancer (TPBC), defined by the co-expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), poses unique therapeutic challenges due to complex signaling interactions and resulting treatment resistance. This review summarizes key findings on the molecular mechanisms and cross-talk among ER, PR, and HER2 pathways, which drive tumor proliferation and resistance to conventional therapies. Current strategies in TPBC treatment, including endocrine and HER2-targeted therapies, are explored alongside emerging approaches such as immunotherapy and CRISPR/Cas9 gene editing. Additionally, we discuss the tumor microenvironment (TME) and its role in treatment resistance, highlighting promising avenues for intervention through combination therapies and predictive biomarkers. By addressing these interdependent pathways and optimizing therapeutic strategies, precision medicine holds significant potential for improving TPBC patient outcomes and advancing individualized cancer care. |
| format | Article |
| id | doaj-art-09b8ebb51a424d269acec0f1f5d0c002 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-09b8ebb51a424d269acec0f1f5d0c0022025-01-07T06:40:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14670331467033Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicineXiu YangDaxin YangXue QiXiujuan LuoGuangmei ZhangTriple-positive breast cancer (TPBC), defined by the co-expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), poses unique therapeutic challenges due to complex signaling interactions and resulting treatment resistance. This review summarizes key findings on the molecular mechanisms and cross-talk among ER, PR, and HER2 pathways, which drive tumor proliferation and resistance to conventional therapies. Current strategies in TPBC treatment, including endocrine and HER2-targeted therapies, are explored alongside emerging approaches such as immunotherapy and CRISPR/Cas9 gene editing. Additionally, we discuss the tumor microenvironment (TME) and its role in treatment resistance, highlighting promising avenues for intervention through combination therapies and predictive biomarkers. By addressing these interdependent pathways and optimizing therapeutic strategies, precision medicine holds significant potential for improving TPBC patient outcomes and advancing individualized cancer care.https://www.frontiersin.org/articles/10.3389/fonc.2024.1467033/fulltriple-positive breast cancermolecular mechanismsendocrine therapy resistanceprecision medicinegene editing (CRISPR/Cas9) |
| spellingShingle | Xiu Yang Daxin Yang Xue Qi Xiujuan Luo Guangmei Zhang Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine Frontiers in Oncology triple-positive breast cancer molecular mechanisms endocrine therapy resistance precision medicine gene editing (CRISPR/Cas9) |
| title | Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine |
| title_full | Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine |
| title_fullStr | Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine |
| title_full_unstemmed | Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine |
| title_short | Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine |
| title_sort | endocrine treatment mechanisms in triple positive breast cancer from targeted therapies to advances in precision medicine |
| topic | triple-positive breast cancer molecular mechanisms endocrine therapy resistance precision medicine gene editing (CRISPR/Cas9) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1467033/full |
| work_keys_str_mv | AT xiuyang endocrinetreatmentmechanismsintriplepositivebreastcancerfromtargetedtherapiestoadvancesinprecisionmedicine AT daxinyang endocrinetreatmentmechanismsintriplepositivebreastcancerfromtargetedtherapiestoadvancesinprecisionmedicine AT xueqi endocrinetreatmentmechanismsintriplepositivebreastcancerfromtargetedtherapiestoadvancesinprecisionmedicine AT xiujuanluo endocrinetreatmentmechanismsintriplepositivebreastcancerfromtargetedtherapiestoadvancesinprecisionmedicine AT guangmeizhang endocrinetreatmentmechanismsintriplepositivebreastcancerfromtargetedtherapiestoadvancesinprecisionmedicine |